Clinical Trials Logo

Progressive Disease clinical trials

View clinical trials related to Progressive Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04033432 Active, not recruiting - Clinical trials for Castration-Resistant Prostate Carcinoma

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: September 20, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.

NCT ID: NCT03586661 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Start date: April 29, 2019
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03154190 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: August 8, 2017
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.